{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T08:18:10Z","timestamp":1768897090862,"version":"3.49.0"},"reference-count":43,"publisher":"Informa UK Limited","issue":"11","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Bioanalysis"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.4155\/bio.14.3","type":"journal-article","created":{"date-parts":[[2014,7,21]],"date-time":"2014-07-21T16:24:21Z","timestamp":1405959861000},"page":"1487-1495","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":23,"title":["Dried Blood Spot Testing: A Novel Approach for The Therapeutic Drug Monitoring of Ziprasidone-Treated Patients"],"prefix":"10.1080","volume":"6","author":[{"given":"Laura","family":"Mercolini","sequence":"first","affiliation":[{"name":"Laboratory of Pharmaco-Toxicological Analysis; Department of Pharmacy & Biotechnology (FaBiT), Alma Mater Studiorum \u2013 University of Bologna, Via Belmeloro 6, 40126Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Mandrioli","sequence":"additional","affiliation":[{"name":"Department for Life Quality Studies (QuVi), Alma Mater Studiorum \u2013 University of Bologna, Corso d\u2019Augusto 237, 47921Rimini, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Protti","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmaco-Toxicological Analysis; Department of Pharmacy & Biotechnology (FaBiT), Alma Mater Studiorum \u2013 University of Bologna, Via Belmeloro 6, 40126Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Conca","sequence":"additional","affiliation":[{"name":"Mental Health Centre (C.S.M.), Local Health Authority of South Tyrol, Bolzano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence J","family":"Albers","sequence":"additional","affiliation":[{"name":"Mental Health Care, VA Long Beach Healthcare System, 5901 East 7th Street, Long Beach, CA90822, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Augusta","family":"Raggi","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmaco-Toxicological Analysis; Department of Pharmacy & Biotechnology (FaBiT), Alma Mater Studiorum \u2013 University of Bologna, Via Belmeloro 6, 40126Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2014,7,21]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.2165\/11632020-000000000-00000"},{"key":"e_1_3_4_4_1","unstructured":"Drugs@FDA. Geodon approval letter (NDA 020825). www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2001\/20825ltr.pdf"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(02)02074-5"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.5.818"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(01)01188-8"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0102"},{"key":"e_1_3_4_9_1","unstructured":"Pfizer Inc. Geodon Prescribing Information Document LAB-0273-21.0. http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=584"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1286287"},{"key":"e_1_3_4_11_1","first-page":"863","article-title":"Metabolism\u00a0and excretion of a new antipsychotic drug, ziprasidone, in humans","volume":"25","author":"Prakash C","year":"1997","unstructured":"Prakash C , KamelA, GummerusJ, WilnerK. Metabolism\u00a0and excretion of a new antipsychotic drug, ziprasidone, in humans. Drug Metab. Dispos. 25, 863\u2013872 (1997).","journal-title":"Drug Metab. Dispos"},{"key":"e_1_3_4_12_1","first-page":"66","article-title":"Ziprasidone and the QTc interval: pharmacokinetic and pharmacodynamic considerations","volume":"35","author":"Kelly DL","year":"2001","unstructured":"Kelly DL , LoveRC. Ziprasidone and the QTc interval: pharmacokinetic and pharmacodynamic considerations. Psychopharmacol. Bull. 35, 66\u201379 (2001).","journal-title":"Psychopharmacol. Bull"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867043456089"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3182708ec5."},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-832687"},{"key":"e_1_3_4_16_1","first-page":"299","article-title":"Advances in therapeutic drug monitoring of atypical antipsychotic drugs","volume":"1","author":"Raggi MA","year":"2004","unstructured":"Raggi MA , MandrioliR, PucciVet al. Advances in therapeutic drug monitoring of atypical antipsychotic drugs. Med. Chem. Rev. 1, 299\u2013316 (2004).","journal-title":"Med. Chem. Rev"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867023369826"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100188"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200013030-00003"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1286281"},{"key":"e_1_3_4_21_1","first-page":"A12","article-title":"Therapeutic drug monitoring use in clinical practice of a mental health service","volume":"21","author":"Merli R","year":"2011","unstructured":"Merli R , HaefeleE. Therapeutic drug monitoring use in clinical practice of a mental health service. Pharmacopsychiatry21, A12\u2013A12 (2011).","journal-title":"Pharmacopsychiatry"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2010.09.037"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2012.11.030"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2003.10.027"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ftd.0000150879.36296.4d"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.571"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2006.05.031"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2007.05.015"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2006.10.024"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.2914"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.999"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2010.11.024"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1452-3981(23)18235-6"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/s110908813"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2007.08.007"},{"key":"e_1_3_4_36_1","first-page":"734","volume-title":"United States Pharmacopeia","year":"2009","unstructured":"United States Pharmacopeia . 32th Edition. United States Pharmacopeial Convention, MD, USA, 734 (2009).\u00a0","edition":"32"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1007669411738"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2010.11.033"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-007-1195-1"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2013.09.019"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e31819e91ce"},{"key":"e_1_3_4_42_1","unstructured":"Arora R HudsonW BoguszewskiP. Hematocrit and its impact on quantitative bioanalysis using dried blood spot technology. Agilent application note 990\u20139630EN (2011). www.chem.agilent.com\/Library\/applications\/5990--9630EN.pdf"},{"key":"e_1_3_4_43_1","unstructured":"Hudson W YongB BoguszewskiP AroraR. Homogeneity of Dried Blood Spots Agilent application note 5990-8306EN (2011). www.chem.agilent.com\/Library\/applications\/5990--8306EN.pdf"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2009.12.007"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10895-011-0855-x"}],"container-title":["Bioanalysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.4155\/bio.14.3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T19:46:54Z","timestamp":1715975214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.4155\/bio.14.3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["10.4155\/bio.14.3"],"URL":"https:\/\/doi.org\/10.4155\/bio.14.3","relation":{},"ISSN":["1757-6180","1757-6199"],"issn-type":[{"value":"1757-6180","type":"print"},{"value":"1757-6199","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ibio20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ibio20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2014-07-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}